On June 16, Abivax S.A. rose 5.03% in regular trading, trading at $102.575/share, with turnover of $79.26 million.

On the news front, the stock is extending a technical rebound after its core drug obefazimod's Phase 3 ABTECT maintenance trial triggered a sharp sell-off earlier this month. The trial, while meeting its primary endpoint with placebo-adjusted clinical remission rates of 39.3% and 40.3% for the 25mg and 50mg dose groups respectively, reported several cancer cases in the 50mg cohort — including prostate cancer, breast cancer, and colonic dysplasia — that sent shares plunging from approximately $130 to around $70, a decline of nearly 50%.

Some investors now argue the cancer cases are more likely correlated with patient age rather than treatment, noting that affected patients averaged 62 years old versus 42 for the overall trial population. This view has supported a gradual recovery from the lows, with buying pressure gaining the upper hand as the market reassesses whether the initial reaction was excessive. The stock remains well below pre-announcement levels amid ongoing securities fraud investigation by The Schall Law Firm.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)